The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Angel | Dead

Total Raised


Last Raised


About OxoN Medica

Developer of drugs for diseases of endothelial dysfunction where interaction between oxidative stress and physiological mediators contributes to the pathology. The company currently has three lead compounds in the advanced stages of pre-clinical development. The targeted therapeutic areas for clinical use of these compounds include diabetic vascular and renal complications, ocular disorders, and respiratory disorders. The company is currently focusing on developing drugs for ocular diseases and its current research will identify new compounds for future development.

OxoN Medica Headquarter Location

P.O. Box 1965

California, 94530,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing OxoN Medica

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

OxoN Medica is included in 1 Expert Collection, including Diabetes.



1,750 items

  • When was OxoN Medica founded?

    OxoN Medica was founded in 1999.

  • What is OxoN Medica's latest funding round?

    OxoN Medica's latest funding round is Angel.

  • How much did OxoN Medica raise?

    OxoN Medica raised a total of $3.9M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.